BioSpace News Archive

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that seven poster presentations from its Alzheimer’s disease/dementia pipeline will be highlighted at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD) on March 26-31 in Lisbon, Portugal.

Pharmacists for Healthier Lives (PfHL) – a coalition of pharmacy organizations seeking to raise consumer awareness of the full-range of essential healthcare services pharmacists provide each day – congratulates PfHL founding member Dr. Lucinda L. Maine on receiving the American Pharmacists Association’s (APhA) 2019 Remington Honor Medal,

Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that the company is celebrating its 10-year anniversary tomorrow, March 23, 2019.

Commercial launch of CODEX® System and Phenoptics™ 2.0 provide the most complete suite of tools for tissue biomarker discovery and translation

Nuo Therapeutics, Inc., provided an update on ongoing interactions with Centers for Medicare & Medicaid Services’ Coverage and Analysis Group representatives.

A leading quality rating for the nation’s hospitals appears not to adequately account for the risks of undergoing certain procedures at certain hospitals, particularly joint replacement surgery, according to a new study

As millions all over the world celebrate World Down Syndrome Day on March 21, two non-profit organizations are taking it one step further

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen Inc.

The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced that the Company expects its previously announced oil products line to be introduced to adult-use consumers in select Canadian markets starting April 2019.

Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 4Q18 and 2018.